Quarterly ResultMay 15, 2026, 08:12 AM
PAVmed Q1 GAAP Net Loss $7.0M; Lucid Revenue $1.3M; Cash $45M
AI Summary
PAVmed Inc. announced its first quarter 2026 financial results, reporting a GAAP net loss of $7.0 million, or $(4.42) per diluted common share. Despite the loss, the company provided positive business updates across its subsidiaries. Lucid Diagnostics generated $1.3 million in EsoGuard revenue and significantly strengthened its balance sheet with a $17 million public offering, boosting proforma cash to $45 million and extending its runway into 2027. Veris Health advanced its implantable physiological monitor towards FDA submission and expanded commercial engagement, while PAVmed relaunched its medical device portfolio.
Key Highlights
- PAVmed reported a Q1 GAAP net loss attributable to common stockholders of $7.0 million.
- Diluted GAAP net loss per common share was $(4.42) for the first quarter of 2026.
- Lucid Diagnostics recognized $1.3 million in EsoGuard revenue from 3,177 tests processed.
- Lucid strengthened its balance sheet with a public offering, netting approximately $17 million.
- Lucid ended Q1 2026 with $45 million in proforma cash, extending its runway into 2027.
- PAVmed's cash and cash equivalents increased to $6.5 million from $1.5 million QoQ.
- Veris Health progressed its implantable physiological monitor development towards FDA 510(k) submission.
- PAVmed relaunched its medical device portfolio, including PortIO and esophageal imaging technology.
Price Impact
More from PAVM